ABSTRACT
The article presents overview of modern concepts about application of artificial intelligence (AI) in pharmacotherapy to decrease risk of developing undesirable side effects of medications. The possibilities of applying AI in selection of optimal medicine or combination of medicines and prediction of treatment results are considered. The choice of the best medicine for patient usually requires integration of data of results of comprehensive examination of patient considering success of genetics and/or proteomics as well as data about chemical descriptors of compounds of medications. The prognosis of medication interactions is often based on indicators of similarity assuming that medications with analogous structures or targets will have comparable behavior or may impede each other. The optimization of scheme of dosage of medicines is implemented applying mathematical models to interpret pharmacokinetic and pharmacodynamic data.
Subject(s)
Artificial Intelligence , Medicine , Humans , ComputersABSTRACT
Cortisol in concentrations within the therapeutic range inhibits calcium response of fibroblast to angiotensin II. In physiological concentrations, cortisol potentiates the effects of angiotensin II via modulation of membrane mineralocorticoid receptors. The inhibitory effects of glucocorticoids on cell proliferation and collagen synthesis are manifestations of its genomic effects mediated by intracellular receptors. The use of glucocorticoid preparation based on nanosized polymer structure made it possible to distinguish between the genomic and nongenomic mechanisms of regulation of activity of target-cells.
Subject(s)
Fibroblasts/physiology , Hydrocortisone/pharmacology , Nanostructures , Angiotensin II/pharmacology , Calcium/metabolism , Cell Proliferation/drug effects , Collagen/biosynthesis , Fibroblasts/drug effects , Hydrocortisone/chemistry , Povidone/chemistry , Receptors, Mineralocorticoid/drug effects , Receptors, Mineralocorticoid/physiologyABSTRACT
The paper presents the current data available on the etiology of tumor diseases, among other things, shows the role of hormones, namely: estrogens and their receptors, in the mechanism responsible for the occurrence of these diseases. Each tumor was shown to have its receptor status and to be unresponsive to this or that therapy differently. The efficiency of treatment and its prognosis may be determined if the receptor composition of an involved organ is estimated correctly. The authors summarize the data available in the literature, as well as the results of their own investigations explaining the selective effect of estradiol receptor agonists and antagonists in various tissues. The mRNA varieties that potentially encoding for the synthesis of different subtypes of estrogen receptors (ER) - ER-α and ERß, which are also coded by various genes located in different chromosomes. Pituitary adenomas as hormone-dependent masses are described in detail. The authors data on the concentration of nuclear estrogen receptors in different types of adenomas are given.
